OasisLMS

ENDO 2026 is intended for the community of practitioners and clinicians who care for patients with hormone disorders as well as scientists advancing endocrine research.

Upon completion of this virtual course, learners should be able to: 

• Discuss state-of-the-art research in endocrinology.
• Practice updated clinical skills for more effective diagnosis, management, and treatment of endocrine disorders and related sequelae.
• Apply updated knowledge and clinical skills in improving patient care.
• Construct new research questions based on updated scientific and clinical advances in endocrinology related disciplines

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Endocrine Society has achieved Accreditation with Commendation.

AMA PRA Category 1 Credit
The Endocrine Society designates each activity in this course for a maximum of 127.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. While offering CME credits noted above, this program is not intended to provide extensive training or certification in the field.

Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.

For questions about content or obtaining CME credit, please contact the Endocrine Society at eventeducation@endocrine.orgv

Statement of Independence 
As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s guideline task force.

Disclosure Policy
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 24 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion. The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The following Annual Meeting Steering Committee members reported relevant financial relationships:

Daniel J. Bernard, PhD, Frontiers in Reproduction (course), Marine Biological Laboratory, Director

Diane Donegan, MB BCh BAO, MRCPI, Corcept, Investigator; Camarus, Advisory board; Recordati, Investigator; Reviews in Endocrinology and Metabolism disorder, Associate Editor

Sean William Fanning, PhD Olema Oncology, Sponsored Research; Onchilles Pharma, Consultancy

Christa E. Flueck, MD, Novo Nordisk, advisor, grantee; Merck, grantee; Pfizer, advisor, grantee; Sandoz, grantee, speaker; EffRx, advisor; Swiss National Science Foundation, grantee; European Society Paediatric Endocrinology, grantee, committee member; Swiss Society of Endocrinology and Diabetology, member, speaker

Oksana Hamidi, DO, Corcept Therapeutics, Advisory Board, occasional non-promotional speaking engagement; Crinetics Pharmaceuticals, Advisory Board; Neurocrine Biosciences, Advisory Board, occasional non-promotional speaking engagement; Recordati Rare Diseases, Advisory Board, occasional non-promotional speaking engagement; Xeris Pharma, Speaking engagement; Camurus, Advisory Board

Edward Chiaming Hsiao, MD, PhD, Corcept Therapeutics, Advisory Board, occasional non-promotional speaking engagement; Crinetics Pharmaceuticals, Advisory Board; Neurocrine Biosciences, Advisory Board, occasional non-promotional speaking engagement; Recordati Rare Diseases, Advisory Board, occasional non-promotional speaking engagement; Xeris Pharma, Speaking engagement; Camurus, Advisory Board

Suzanne Jan De Beur, MD, Current Osteoporosis Reports, Associate Editor; Ultragenyx, research, Advisory Board, Coordinating Author, consulting; Mereo research; Kyowa Kirin, Advisory Board, research, DSMB; NIH, DSMB, PI, key personnel, grant reviewer; FDA, grant review; PCORI, Investigator; Ascendis, Advisory Board

Peter Kamenicky, MD, PhD, Governmental: Inserm, member of commission scientifique spécialisée CSS3; Pfizer, speaker and congress invitation; Amolyt Pharma, investigator, speaker and congress invitation; Ascendis Pharma, advisory board

Katja Kiseljak-Vassiliades, DO, HRA Pharma, Adrenocortical Carcinoma Advisory Board

Raghavendra Mirmira, PhD, MD, Journal of Clinical Endocrinology and Metabolism, Deputy Editor; Journal of Clinical Investigation, Associate Editor; Veralox Therapeutics, Scientific Advisory Board; MilliporeSigma, royalties for the development of an antibody

Connie Newman, MD, Consultant Food and Drug Association (FDA) for Endocrinologic and Metabolic Diseases Advisory Committee; Honorarium of $500 from Federation of Medical Women of Canada Sept 2023

Theodora Pappa, MD, PhD, Endocrine Fellows Foundation, Board of Directors

Elizabeth Pearce, MD, MSc, Iodine Global Network: member of Management Council; Deputy Editor JCEM; Dynamed thyroid content editor; National Dairy Council, honoraria for speaking; Merck China Symposium, honoraria for speaking

Luca Persani, MD, PhD, Merck, speaker at scientific meeting & advisory boards in 2024 and 2025; Sandoz, Scientific Board of IDEE 2024 meeting; Egetis, advisory board

Laura Torchen, MD, Levo Therapeutics, site PI for carbetocin clinical trial; IBSA Pharma, site PI for Tirosint Sol clinical trial

Elena Tsourdi, MD, PhD, Clinical Studies: Amgen; Kyowa Kirin, UCB, Alexion; Ascendis; Advisory Boards and Lectures: Amgen, UCB, Ascendis; Educational Grants: UCB, Takeda, Ascendis

Adina Turcu, MD, NIH (NIDDK, NHLBI), grantee; DDF, grantee; ESAP questions writer; JCEMCR- Deputy Editor; AstraZeneca, Consultant

Jun Yang, MBBS, PhD, FRACP, AstraZeneca - Advisory Group (compensation directly paid to Hudson Institute of Medical Research for research); NovoNordisk - speaking engagement; Y (compensation directly paid to Hudson Institute of Medical Research for research)

The following AMSC members reported no relevant financial relationships:

Ana Paula Abreu, MD, PhD; Francisca Acosta, PhD; Jadailne Bermudez-Santos, MD; Olga Astapova, MD, PhD; Laura Boucai, MD; Ana Canton, MD, PhD; Barbara Gisella Carranza Leon, MD;  E. Danielle Dean, PhD; David A. Ehrman, MD; Daniel Guy Gioeli, PhD; Nils Halberg, PhD; Hebatullah Ismail, MD; Srividya Kidambi, MD;  Richard McCosh, PhD; Michelle McDonald, PhD; Erik Nelson, BSc, PhD; Gladys Palaguachi, MD; Ines Pineda Torra, PhD;  Julie Refardt, MD, PhD; Rebecca Riggins, PhD; Kanakadurga Singer, MD;  Ya-Xiong Tao, PhD; Anisley Valenciaga, MD, PhD; Elizabeth Wellberg, PhD; and Corrine Welt, MD.

Disclosure information for presenters is included in their individual recorded presentations.

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.